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CMV = cytomegalovirus; FNHTR = febrile nonhemolytic transfusion reaction; nvCJD = new variant Creutzfeldt–Jakob disease; RBC = red blood
cell; WBC = white blood cell; SSI = surgical site infection; TRIM = transfusion-related immune modulation.
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Introduction
Blood transfusion remains a common event in current medical
practice. Between 10 and 14 million units of blood are
donated annually in the USA, and 3–4 million people receive
blood transfusions every year [1,2]. Transfusion administra-
tion in surgical and critical care settings is particularly fre-
quent and, although they vary substantially, primarily
according to the specific surgical population studied, series
show that transfusion is used in 30–100% of patients [3].
Despite a general trend toward a decreased number of trans-
fusions per year, operations in older patients and those with
more comorbidities ensures that blood transfusion will fre-
quently be used in these surgical settings.
Blood transfusions carry significant risks. Among these, trans-
mission of infectious organisms (e.g. viral or bacterial)
remains one of the most feared complications. Also, studies
from the 1970s proved that blood transfusion can cause
immune suppression, as evidenced by a reduced immuno-
logic response and improved outcome in kidney transplant
recipients who had previously been transfused [4]. More
recently, specific studies looking at the immunosuppressive
effect of blood transfusion have raised new questions for the
practice of transfusion in today’s medicine.
This article reviews the infectious risks associated with blood
transfusion and analyzes the most recent data on its immuno-
logic effects, specifically on cancer recurrence, mortality, and
postoperative infections in surgical patients. We also review
the use of leukoreduction in blood transfusion and its role in
preventing transfusion-transmitted infections and immuno-
modulatory complications.
Infectious risks of blood transfusion
Any intravenously administered fluid can transmit infection,
but blood is a uniquely nutritious medium and is seemingly an
excellent means for transmitting infection. In fact, any
pathogen that is capable of existing in blood can be transmit-
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Abstract
Blood transfusions remain common practice in the critical care and surgical settings. Transfusions
carry significant risks, including risks for transmission of infectious agents and immune suppression.
Transmission of bacterial infections, although rare, is the most common adverse event with transfusion.
The risk for transmission of viral infections has decreased over time, clearly because tests are
becoming more sensitive in detecting certain viral infections such as hepatitis B, hepatitis C, and HIV.
Several immunomodulatory effects are thought to be related to transfusions, and these can result in
cancer recurrence, mortality, and postoperative infections. Numerous studies have been performed to
examine the role of leukoreduction in decreasing these transfusion-related complications but results
remain contradictory. We review the infectious risks associated with blood transfusion and the most
recent data on its immunologic effects, specifically on cancer recurrence, mortality, and postoperative
infections in surgical patients. We also review the use of leukoreduction in blood transfusion and its
role in preventing transfusion-transmitted infections and immunomodulatory complications.
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ted in this manner. It is a tribute to modern blood banking pro-
cedures that transfusion-transmitted infection is actually quite
rare. Blood-borne parasites can be transmitted with transfu-
sion, and a handful of cases of malaria, babesiosis, Chagas’
disease, trypanosomiasis, and toxoplasmosis have been
reported. The primary means of preventing these infections is
through careful screening of donors, especially those who
have traveled to areas that are endemic for these diseases
[5]. Syphilis can be transmitted by blood transfusion but no
cases have been reported since 1969; it is generally thought
that the practice of refrigerating blood, which kills spirochetes
within 1–2 days, is responsible for this.
Bacterial contamination is the second most frequently
reported cause of blood transfusion-related death after
hemolytic reactions, and it accounts for more than 10% of
transfusion-associated deaths in the USA [6]. The Assess-
ment of the Frequency of Blood Component Bacterial Conta-
mination Associated with Transfusion Reaction Study
(BaCon), which was implemented by the US Centers for
Disease Control and Prevention, was the first study to look at
specific characteristics related to bacterial contamination of
blood products [7]. Results from data collected between
1998 and 2000 showed that the risk for transfusion-transmit-
ted bacteremia is 1 in 100,000 units of platelets and 1 in
500,000 units of red blood cells (RBCs), and that the esti-
mated risk for death from bacterial transfusion-transmitted
causes is 1 in 500,000 units of platelets and 1 in 8 million
units of RBCs. Contamination with Gram-positive bacteria
was more common; however, Gram-negative contamination
was independently associated with increased risk for death.
Rigors, fever, or tachycardia within 4 hours of transfusion
were present in at least 75% of the cases, and haziness or
discoloration of the blood product was present in 24% of the
contaminated units [7].
Previous reports of small case series showed that Gram-neg-
ative bacteria appeared to be the most common source of
blood component contamination. However, as shown by the
BaCon study, this is not true and these reports might have
been biased by the fact that Gram-negative bacteria are more
frequently associated with death and hence are reported
more often. Actually, Gram-positive bacteria, including
Staphylococcus and Streptococcus spp., as well as Gram-
negative bacteria including Escherichia coli, and Serratia,
Enterobacter, and Yersinia spp., have all been implicated in
blood contamination. In general, if bacteremia or endotoxemia
is suspected after transfusion of a unit of blood or platelets,
then the remaining blood/platelets in the bag and/or tubing
should be examined by stain and cultured. In addition, the
recipient’s blood should also be cultured.
Unlike bacterial infections, viral infections are not immediately
evident. Hepatitis B was once the most serious transfusion
risk, but the development many years ago of a sensitive and
specific test for hepatitis B has led to a dramatic reduction in
the transmission of this infection via transfusion. After the
introduction of tests for hepatitis B antigen and antibody,
non-A/non-B hepatitis became the most prevalent form of
transfusion-transmitted infection. For a period, the risk for
developing non-A/non-B hepatitis was estimated to be
approximately 7% for recipients of volunteer-donated blood
and 28% for recipients of commercial blood [8,9]. The avail-
ability of increasingly sensitive and specific tests for hepatitis
C has greatly reduced this risk as well.
The spread of HIV in the 1980s introduced a new risk for viral
infection into the equation for blood transfusion. Again,
increasingly sensitive and specific tests have become avail-
able, and the absolute risk for acquiring transfusion-associ-
ated HIV infection has become quite low, accounting for
fewer deaths in the current era than post-transfusion hepati-
tis. However, the possibility of transfusion-associated HIV is
still much more frightening to most patients and many practi-
tioners. Prevention of transfusion-associated HIV infection is
accomplished first through careful screening of all potential
donors to eliminate those at high risk for having the infection,
and second by screening all donated units for antibodies to
HIV. It has been estimated that predonation screening is 98%
effective in preventing the donation of positive units and that
antibody testing is 95% effective, providing a combined
effectiveness of approximately 99.9% [10]. Using these tech-
niques only, between 1985 and 1988 – a time when the
overall prevalence of HIV infection in the USA was increasing –
post-transfusion HIV infections were reduced by 76%.
The only remaining real risk for acquiring HIV through blood
transfusion comes from the small possibility that blood could
be donated during the so-called window of sero-negativity
between the time when HIV infection occurs and detectable
antibodies develop. The average window is estimated to be
about 8 weeks [10]. The incidence of positive units of blood
discovered through postdonation screening has been steadily
decreasing. The risk for blood being sero-negative but virus-
positive is assumed to be proportional to the number of sero-
positive units discovered through post-transfusion antibody
screening. In one study [11] conducted at five blood centers
across the USA, 2,318,356 units of blood derived from
586,507 donors were tested between 1991 and 1993. In that
study, the risk for acquiring an HIV infection from a unit of blood
was 1 in 493,000, the risk for hepatitis C was 1 in 103,000,
and the risk for hepatitis B was 1 in 63,000. The combined risk
for acquiring any type of viral infection was 1 in 34,000, and
88% of that risk was derived from hepatitis B and C.
Current risks with improved, more sensitive tests are consid-
ered to be even lower (Table 1). Busch and colleagues [12]
reported that risk estimates are now based on mathematical
models. These model-based estimates indicate that the
current risk for HIV is 1 in 1,800,000, for hepatitis C it is 1 in
1,600,000, and for hepatitis B it is 1 in 220,000. Using the
newest nucleic acid technology screening techniques, theS20
Critical Care    June 2004 Vol 8 Suppl 2 Dellinger and Anaya
window during which infection is not detectable in a donated
unit of blood has decreased to 11 days for HIV and 8–10 days
for hepatitis C virus [12]. The risk for a fatal hemolytic trans-
fusion reaction is estimated to be 1 in 100,000 [13]. Thus, it
can be seen that after transfusion the risk for death from
hepatitis B or C, or from a hemolytic transfusion reaction, is
greater than the risk for dying from transfusion-associated HIV.
One of the most recent potential infectious agents in blood
transfusion to be proposed is the prion agent of the new
variant Creutzfeldt–Jakob disease (nvCJD). To date, no evi-
dence of transfusion-mediated transmission of classic CJD
has been found. However, the disease has been transmitted
through corneal transplants, human growth hormone derived
from human pituitary glands, dura mater transplants, and inad-
equately sterilized depth electrodes used in the brain during
the work-up and treatment of epilepsy. Because experience
with nvCJD is so limited and because it appears to have pre-
viously unreported modes of transmission, some authorities
have enacted precautionary donor exclusion regulations
[14,15] and some countries have even changed their practice
to universal leukoreduction [16].
More recently, transfusion-transmitted West Nile Virus was
confirmed within the USA. Since screening began in June
2003, 163 highly reactive units were removed from a total of
1.1 million units screened during a 2-month period. The inves-
tigations into West Nile Virus transmission, as well as the fast
implementation of a screening test and preventive strategies,
are all examples of the significant advances in blood transfu-
sion medicine and highlight the need for a multidisciplinary
approach to prevent transfusion-mediated infectious compli-
cations [17,18].
On the whole, transfusion is a very safe treatment modality.
For those patients and physicians who wish to keep the risk
for transfusion-associated infection to a minimum, the primary
response should be to limit unnecessary transfusion. Another
response has been to increase donation of autologous blood
for transfusion. Although the practice of autologous blood
donation appears to have reached a plateau over the past
10 years, analysis of transfusion practices in the USA has
revealed that the number of autologous units donated
increased more than 30-fold from 1980 to 1992 [1,19,20].
Immunologic consequences of blood
transfusion
Since the early 1970s, transfusion of blood and blood products
has been linked to immune suppression [4]. Specific immuno-
modulatory effects thought to be related to transfusions
include increased cancer recurrence, increased mortality,
increased postoperative bacterial infections, decreased recur-
rence rate of Crohn’s disease, and decreased risk for recur-
rent spontaneous abortion. This whole constellation of immune
effects associated with transfusion has been referred to as the
‘TRIM’ effect (transfusion-related immune modulation).
A unit of donated blood is usually fractionated into its differ-
ent components. When fractionated, it can be separated into
RBCs, buffy coat (containing white blood cells [WBCs] and
platelets) and plasma, or into RBCs (with buffy coat) and
plasma. Buffy-coat-free RBCs (a technique mostly used in
European countries) have a 75% reduction in WBCs, result-
ing in approximately 109 leukocytes/unit. To reduce effec-
tively the number of leukocytes in order to prevent
alloimmunization and transmission of viruses, leukocyte filters
are used, which remove 99.9% of WBCs, resulting in approx-
imately 106 leukocytes/unit in a RBC suspension.
Particular interest has been directed toward the role of
WBCs in allogeneic blood and the risk of the TRIM complica-
tions [21]. The specific mechanism by which this occurs
remains elusive, although multiple hypotheses have been for-
mulated, including allogeneic WBC apoptosis with cytokine
release and immunologically active allogeneic WBCs, among
others. Studies performed to evaluate the effect of WBCs
present in allogeneic blood traditionally compare transfusions
with either RBCs or buffy-coat depleted RBCs (common in
Europe) with transfusion of autologous RBCs or WBC
depleted RBCs, which are considered to be equally non-
immunogenic, for this purpose.
Various studies have looked at cancer recurrence and blood
transfusion. Three randomized clinical trials comparing buffy-
coat reduced RBCs versus autologous whole blood [22],
WBC-reduced RBCs [23], or autologous RBCs [24] in
patients with colorectal cancer, and two recent meta-analy-
ses [3,25] showed independently that there was no differ-
ence in risk for recurrence between the WBC reduced group
and the other groups studied. The fact that the three studies
were very homogeneous with regard to patient population
and recurrence rates makes these results even more reliable.
However, it is not known whether there might be a difference
in recurrence rate between WBC reduced RBCs and RBCs
with buffy coat, as some experimental studies have sug-
gested [26], which would be more relevant to practice stan-
dards in the USA.
Mortality has also been compared between patients receiving
transfusions of allogeneic blood and those receiving WBC
reduced blood. In a study of patients undergoing cardiac
Table 1
Infectious transmission risks with blood transfusion
Agent transmitted Estimated risk
Bacterial 1 in 100,000-500,000
Hepatitis B 1 in 220,000
Hepatitis C 1 in 1,600,000
HIV 1 in 1,800,000
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surgery in which infection rates were compared between
buffy-coat reduced RBCs and WBC reduced RBCs, Van de
Watering and coworkers [27] found an increased risk for
mortality not related to infections in patients with non-WBC-
reduced blood. Two other similar studies [23,28] also
showed a trend toward increased mortality with the use of
non-WBC-reduced blood. However, these studies were not
initially designed to evaluate differences in mortality, and
prognostic factors may not have been distributed equally in
the different groups or confounding factors may not have
been included for this analysis.
Recently, Hebert and colleagues published the results of a
retrospective cohort study conducted to evaluate experience
in Canada following adoption of universal leukoreduction. The
results show a reduction in mortality from the period before
implementation of leukoreduction to current practice [29].
However, similar studies have yielded conflicting results. Dzik
and coworkers [30] showed no significant difference in mor-
tality between patients receiving non-leukoreduced blood and
those receiving leukoreduced blood. Similarly, Baron and
coworkers [31] found no difference in mortality in their study,
in which a before-and-after study design was used to evalu-
ate the impact of leukoreduction on patients undergoing
abdominal aortic surgery. More recently, Vamvakas [32]
reported a meta-analysis that included 14 randomized con-
trolled trials evaluating mortality in patients receiving WBC-
reduced and non-WBC-reduced transfusions. Although no
mortality difference was found, a subgroup analysis revealed
that non-WBC-reduced transfusion was associated with
increased short-term mortality in patients undergoing open
heart surgery. Overall, there does not appear to be an associ-
ation between allogeneic non-WBC-reduced transfusions
and mortality, but further studies must be done to address
this question specifically for subsets of patients.
Surgical site infection (SSI) remains the most common
infectious complication in surgical patients and is associ-
ated with significant morbidity, mortality, and resource uti-
lization. SSI is a measurable common complication in
surgical patients and is a surrogate for other postoperative
infections. Transfusion has traditionally been considered a
risk factor for SSI [33]. Observational studies [34,35] have
shown this association over time and more recent studies
(including a meta-analysis) [36–39], with greater numbers
of patients followed, continue to corroborate this relation-
ship.
At least 12 randomized controlled trials and two meta-analy-
ses have been reported that evaluated the role of allogeneic
versus WBC reduced blood in postoperative infections
[3,22–24,27,31,40–49]. The results are conflicting and
meta-analyses are not applicable, given the heterogeneous
characteristics of the different studies regarding patient pop-
ulation, infections definitions, study design, infection rates,
and other factors.
Most of the studies show either a small increase or no signifi-
cant difference in infection risk with non-WBC-reduced trans-
fusion. Two studies, however, conducted by Jensen and
coworkers [40,41] showed a significantly increased risk for
postoperative infection with non-WBC-reduced blood trans-
fusion. They evaluated the rate of SSI in patients undergoing
colorectal surgery. In one of the studies [41], one group of
patients received buffy-coat depleted RBCs (control group)
and was compared with another group that received WBC
reduced RBCs. Patients who received WBC reduced trans-
fusions had no SSIs whereas the control group developed
significantly more infectious complications (18.3%). This was
a prospective and randomized study; however, it has been
criticized for having uncontrolled confounding factors, giving
non-leukoreduction an implausible cause–effect association
in the risk for SSI.
Moreover, other well designed studies have not been able to
show a significant association between the use of non-WBC-
reduced blood transfusions and risk for postoperative infec-
tions. Wallis and coworkers [47] conducted a prospective,
randomized controlled trial that compared postoperative
infection rates in patients undergoing coronary or heart valve
surgery. Patients were randomly assigned to receive plasma
reduced, buffy-coat reduced, or WBC reduced blood. Post-
operative infections overall were more common in patients
with plasma reduced blood transfusion. However, when urinary
tract infections were excluded, no significant difference was
seen across the three groups.
Results from the two published meta-analyses [3,49], from
which the studies by Jensen and coworkers were excluded,
indicate no significant differences in postoperative infections
between the WBC reduced group and the control group.
Nevertheless, some very well designed studies [27] show a
statistically significant decrease in postoperative infections
with the use of WBC reduced blood, and more well designed
and comparable randomized, controlled trials must be done
to elucidate this question.
Leukoreduction practices in blood transfusion
There is enough evidence to support the contention that
transfusion of WBC depleted allogeneic blood decreases the
risk for febrile nonhemolytic transfusion reactions (FNHTRs),
cytomegalovirus (CMV) transmission, and platelet refractori-
ness due to HLA alloimmunization. In 1999, the UK, Ireland,
and Portugal implemented universal leukoreduction of all
blood components with the goal of preventing the theoretical
risk for nvCJD transmission. At the same time, France and
Canada also implemented leukoreduction, just as means of
making blood transfusion a safer practice [16].
In the USA, the Advisory Committee on Blood Safety and
Availability to the US Food and Drug Administration has rec-
ommended universal leukoreduction and has noted that its
use is justified from a benefit-to-risk perspective [50]. However,
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multiple experts in the area have expressed disagreement
with this view when justified only by current data [51]. The
role of leukoreduction in preventing nvCJD is not supported
by the literature, and if universal leukoreduction is to be imple-
mented for reasons beyond its three proven benefits
(FNHTRs, CMV transmission, and platelet refractoriness)
then it will probably be based on its immunomodulatory
effects. It has not been shown that cancer recurrence is
decreased by leukoreduction practices. Mortality and post-
operative infections still remain the most attractive reasons to
implement this practice, but to date there is not enough evi-
dence to support this practice when based solely on those
two effects and further studies are needed.
Conclusion
Overall, blood transfusion is a safe treatment option.
Increased donor selection criteria and increased screening of
donated blood have led to a decrease in the rate of transfu-
sion-related infections. However, unnecessary transfusion
should be avoided to further reduce the risk for infection and
other complications. Several studies have looked at immune
effects associated with transfusion. These studies compare
different blood preparations to examine the role that WBCs
have in the development of certain complications. Universal
leukoreduction has been instituted in many countries and has
been recommended by an advisory committee to the US
Food and Drug Administration in the USA. It decreases the
rate of FNHTRs, the risk of CMV transmission, and the unre-
sponsiveness of platelet transfusion after previous alloimmu-
nization. However, leukoreduction does not appear to play a
role in risk for cancer recurrence, and further studies must be
done to better determine its role in mortality and postoperative
infections, particularly in specific subsets of surgical patients.
The practice of universal leukoreduction based on a cost-
effectiveness perspective is still debated, and the variability of
results when studying its effects on mortality and postopera-
tive infections calls for future and better designed studies.
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